Roche deal fails to Repare the licensing scene
Few sizeable transactions have emerged so far this year, with small licensing deals looking like the norm.
Abbvie to become the biggest of pharmas in 2028
New extended consensus forecasts from Evaluate Pharma show Roche edged out of first place by Abbvie as new blood replaces Humira.
The patent winter is coming
Biopharma is approaching the most painful period of patent loss for at least 30 years. Is M&A an answer?
Diagnostics beat implants in the race to market
Roche had the most innovative approvals over the last five years – but took second place in terms of speed.
Investors bite the big pharma hands that feed them
Spending heavily on buybacks and dividends does not mean sector-leading share price performance, Evaluate Vantage finds.
Big pharma’s biggest spenders revealed
Bristol Myers Squibb has spent the most on M&A, R&D and licensing since 2017, and Eli Lilly the least. Guess which strategy is working best.
Covid drives a record jump in research spending for big pharma
A second year of pandemic investments helped big pharma’s combined R&D bill surge above $100bn for the first time.
For medtechs seeking deals, it’s hurry up and wait
Last year venture-backed companies waited longer than average for a takeout, and longer than ever for an IPO.
